Global Stem Cells Group Announces Partnership with Bioscience Cell Factory

Global Stem Cells Group (GSCG) has signed a historic agreement with a company known as Bioscience Cell Factor- this Dubai-based healthcare company will allow GSCG to act as their representatives operating in both the Middle East and Latin America.
[Global Stem Cells Group]
Press Release
Bookmark

No account yet? Register

0
Share

MammaPrint® Approved for Reimbursement in Germany

Agendia, Inc. announced that the Federal Joint Committee approved MammaPrint®, Agendia’s 70-Gene Breast Cancer Recurrence Assay.
[Agendia, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Latin America’s Embrace of an Unproven COVID Treatment Is Hindering Drug Trials

Unchecked ivermectin use in the region is making it difficult to test the anti-parasite drug’s effectiveness against the coronavirus.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

In New Strategy, Wellcome Trust Will Take On Global Health Challenges

One of the world’s largest nongovernmental funders of science, the Wellcome Trust, is enlarging its focus to include goal-oriented, as well as basic research. The London-based philanthropy, which spends more than £1 billion per year, said today it will boost funding for research on infectious diseases, the health effects of global warming, and mental health.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

Dozens to Be Deliberately Infected With Coronavirus in UK ‘Human Challenge’ Trials

Proponents of the trials say they can be run safely and help to identify effective vaccines, but others have questioned their value.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase I Study Results with VAC2 for the Treatment of Non-Small Cell Lung Cancer

Lineage Cell Therapeutics, Inc. and Cancer Research UK have announced encouraging preliminary results from an ongoing Phase I clinical study of VAC2 in non-small cell lung cancer (NSCLC). Produced from a pluripotent cell technology using a directed differentiation method, VAC2 has demonstrated remarkably potent induction of immune responses in all patients dosed to date.
[nan]
Press Release
Bookmark

No account yet? Register

0
Share

Ezra Receives FDA Clearance For Prostate Cancer Artificial Intelligence

Ezra announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence (AI), designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first Prostate AI to ever be cleared by the FDA.
[Ezra (PR Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Stabler Awarded R01 Grant From the NIH NIDDKD

Congratulations to Cherie Stabler, Ph.D., professor in the J. Crayton Pruitt Family Department of Biomedical Engineering, for receiving a $1.7 million RO1 grant from the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for her project, “Engineering Immunomodulatory Nanoscale Coatings for Protecting Islet Transplants.”
[The University of Florida]
Press Release
Bookmark

No account yet? Register

0
Share

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. announced the withdrawal of its European Marketing Authorization Application for TIBSOVO® for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
[Agios Pharmaceuticals, Inc]
Press Release
Bookmark

No account yet? Register

0
Share

The Unsung Heroes of the Nobel-Winning Hepatitis C Discovery

A tight-knit team of scientists worked feverishly to identify the deadly virus. Only one of them was awarded the Nobel.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

Cyclo Therapeutics Phase III Pivotal Program Can Begin Enrollment per US FDA

Cyclo Therapeutics, Inc. received notification from the US FDA that enrollment could proceed for its Phase III global pivotal clinical trial, “A Phase III, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1”.
[Cyclo Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share